Navigation Links
Intarcia Therapeutics Announces Final Results From a Phase 2 Study,of Injectable Omega Interferon plus Ribavirin for the Treatment of,Hepatitis C Genotype-1

ients."

About Omega DUROS Therapy

Omega DUROS therapy is being developed to improve the treatment of HCV by offering a more convenient and potentially safer and more effective treatment. Omega DUROS therapy is designed to deliver a continuous and consistent dose of omega interferon for three months via the implantable DUROS device, a drug delivery technology developed by ALZA Corporation, and licensed to Intarcia for use in certain broad fields. Another product incorporating the DUROS technology has already approved by the FDA for the palliative treatment of prostate cancer. Intarcia is also leveraging the DUROS technology in evaluating other drug development opportunities. The most advanced of these is focused on the delivery of GLP-1 and a GLP-1 analog with the DUROS device for the treatment of type 2 diabetes.

About Intarcia

Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapeutics for patients with chronic diseases in which there are significant unmet medical needs. Intarcia's drug development expertise and competitive edge are complemented by its ability to stabilize macromolecules and to deliver them in a constant and consistent manner via the proprietary DUROS drug delivery platform. The initial programs that Intarcia is pursuing are in hepatitis C and type 2 diabetes.

About Hepatitis C

Hepatitis C is a major global public health problem. According to the World Health Organization, more than 170 million people worldwide are chronically infected with HCV, and three to four million new HCV infections occur annually. The U.S. Centers for Disease Control and Prevention has estimated that in the United States approximately 3.4 million people are chronically infected with HCV and approximately 25,000 new patients are infected each year. It is estimated that 10,000 to 12,000 patients die annually in the United States from complications resulting from HCV infection. The current standard of care for tr
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Intarcia Therapeutics Announces Presentation of Final Results From a Phase 2 Combination Study for the Treatment of Hepatitis C at the Digestive Disease Week Conference
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Post Your Comments:
(Date:12/22/2014)... 22, 2014 Cyberonics, Inc. (NASDAQ: CYBX ... and management of epilepsy, today announced it will participate in ... Wednesday, January 14, 2015, in San Francisco ... Chief Executive Officer, will speak at 11:00 AM Pacific Time.  ... by clicking on the Investor Relations link on the Cyberonics ...
(Date:12/22/2014)... , Dec. 22, 2014  Pfenex Inc. (NYSE MKT: ... anthrax vaccine, has been filed and is now open ... by the Department of Health and Human Services (HHS), ... "We are extremely pleased to have the ... This represents a significant milestone in our company,s partnership ...
(Date:12/19/2014)... Calif. , Dec. 19, 2014  Newport ... that Siddhartha Kadia, Ph.D. has joined the company,s ... Chief Executive Officer and a director of Evans ... laboratory testing, evaluation and analytical services to companies ... Prior to joining Evans Analytical Group, Dr. ...
Breaking Medicine Technology:Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 2Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 3Siddhartha Kadia, Ph.D. Joins Board of Directors of Newport Corporation 2
... MADISON, N.J. and CYPRESS, Calif., April 11, 2012  Quest ... provider of diagnostic testing, information and services, today announced ... granted 510(k) clearance to its Simplexa C. difficile ... The test, from the company,s Focus ...
... MIAMI, April 11, 2012  One of the responsibilities of ... and dogs against heartworm disease . While many ... understand how preventative heartworm treatments actually work. ... provides the following five tips and safety measures ...
Cached Medicine Technology:FDA Clears the Quest Diagnostics Simplexa® C. difficile Molecular Test 2FDA Clears the Quest Diagnostics Simplexa® C. difficile Molecular Test 3petMD.com Celebrates Heartworm Awareness Month with Five Heartworm Prevention Tips for Pet Owners 2petMD.com Celebrates Heartworm Awareness Month with Five Heartworm Prevention Tips for Pet Owners 3
(Date:12/22/2014)... 2014 Explorys, the leader in big ... leadership team: Greg Yarrington as Vice President of Operations, ... Wells as Vice President of Solutions. These new leaders ... jobs in 2015 to support client demand for the ... offerings, and growth of its partner network. , ...
(Date:12/22/2014)... 2014 Pasadena sleep apnea ... sleep apnea. Drowsy drivers are 15 times more likely ... well-rested, and some experts believe that sleep-deprived drivers may ... drivers. Unfortunately, millions of Americans may be sleep-deprived without ... Sleep Medicine, about 18 million Americans have sleep apnea, ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Christmas is days ... has a fast and easy solution that will please: the ... can be purchased from from $25 up to $350," says ... 100% customer satisfaction and a wide array of skin care ... fees and no expiration dates. , Gift delivery past ...
(Date:12/22/2014)... Washington, DC (PRWEB) December 22, 2014 ... Nursing Leadership Conference, next month in San ... strategies to address dynamics that often stand in ... authority, and competition. , This premier faculty ... Center for Transformational Leadership, whose mission is to ...
(Date:12/21/2014)... 2014 BellasDress.com offers a wide range ... Today, it announces its BellasDress Christmas Sale , ... online store. , BellasDress is a famous online supplier ... fans through a series of promotions. The dress experts ... , “We are proud of offering high quality ...
Breaking Medicine News(10 mins):Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 3Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:2015 NLN Leadership Conference February 5-7 San Antonio 2Health News:2015 NLN Leadership Conference February 5-7 San Antonio 3Health News:BellasDress.com Announces its BellasDress Christmas Sale 2
... LYMAN, S.C., Sept. 11 Southern Home Medical,Equipment, Inc. ... the month of August 2008 compared to July 2008., ... stated, "On the heels of,reporting record sales in the ... on a path of strong sales momentum. Encore Medical ...
... against women in a family also has serious consequences ... sling Monemi from Uppsala University has studied women and ... other things, that children whose mothers are exposed to ... other children. , Kajsa sling Monemi, paediatrician, the ...
... - For Non-US Healthcare Media, - Global ... Improved Survival Outcomes With Vetmedin(R) (pimobendan), Veterinarians and ... promise of an extended happy life together for millions ... that dogs,suffering from the most common type of heart ...
... Residents to Eat Right, Move More ... and Milk Their Diets, BOSTON, Sept. 11 ... fad diets -- which seem to go in and out of,fashion like shoulder ... -- including 51 percent of Massachusetts,residents -- remain overweight or obese., A ...
... 11 Oculus Innovative,Sciences, Inc. (Nasdaq: OCLS ), ... of products based upon the Microcyn(R),Technology platform, today announced ... exclusive interview on WallSt.net,s 3-Minute Press Show., The ... the,significance of the company,s latest press release., ...
... Plastic surgeon offers the surprise scoop, NEW ... time and an,active lifestyle can impact a person,s ... million Americans turned to cosmetic procedures last,year to ... Shirley Madhere, M.D., says you can improve your ...
Cached Medicine News:Health News:Southern Home Medical Announces Revenues Up 172% for the Month of August 2Health News:Landmark Research Heralds New Era in Dog Heart Treatment and Longer Life for Dogs 2Health News:Landmark Research Heralds New Era in Dog Heart Treatment and Longer Life for Dogs 3Health News:Landmark Research Heralds New Era in Dog Heart Treatment and Longer Life for Dogs 4Health News:Message to Boston Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Boston Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:Message to Boston Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 4Health News:[video] Hojabr Alimi, CEO of Oculus Innovative Sciences, Inc. Discusses Reduction of Planned Expenses on WallSt.net's 3-Minute Press Show 2Health News:Insider Secrets for Beautiful Skin 2
... RELISA ENA Multiparameter Kit is ... for six of the most ... a unique quality control system. ... Check) well in each strip ...
... RELISA ENA assays were designed with the ... clinician in the diagnosis of autoimmune disease. ... disease and 1,000 normal individuals were tested ... Test System. Immuno Concepts compared the results ...
... functional human C1q coated in the solid phase ... stage, CIC in the diluted patient samples and ... into the C1q coated assay wells. After incubation, ... and a ready to use conjugate (goat anti-human ...
... CIC are formed as a host ... cleared by phagocytosis. If not cleared, CIC ... inflammatory response. CIC are increased in Systemic ... may be involved in other autoimmune disorders ...
Medicine Products: